ClinicalTrials.gg
RecruitingNCT05582993Updated Sep 9, 2026

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

A Phase 3 interventional study of Vonicog Alfa and ADVATE in Von Willebrand Disease (VWD), sponsored by Takeda. Recruiting at 23 sites in 6 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in von Willebrand Diseases by Takeda — 3 open to participants now, 3 under way, 2 of them phase 3. von Willebrand Diseases · Takeda.

Started
2024
the only one that year
Phase 3
7 of 13
2 open now
Registered
8th of 13
by date

Among the 13 studies in von Willebrand Diseases by Takeda, this one is the only one that started in 2024, is one of 7 in phase 3, and was the 8th registered.

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

Browse von Willebrand Diseases studies →

Open to participants now

3 of the 13 studies in von Willebrand Diseases by Takeda are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in von Willebrand Diseases by Takeda, or all of them as a file.
02

Study summary

The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor [rVWF]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months.

During the study, participants will visit the study clinic 5 times after treatment initiation.

03

Conditions studied

  • Von Willebrand Disease (VWD)
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. The participant has a documented diagnosis of severe VWD (baseline von Willebrand factor ristocetin cofactor activity [VWF:RCo] \<20 international units per deciliter [IU/dL]) with a history of replacement therapy with VWF concentrate required to control bleeding and a diagnosis of VWD type 1, type 2 (2A, 2B, 2M, 2N), or type 3. Diagnosis is confirmed, as applicable, by genetic testing and/or by multimer analysis, which may be documented in participant's history or at screening.
  2. The participant is \<18 years of age at the time of screening.
  3. Prescreening treatment requirements:

    1. The participant has been receiving OD therapy with VWF products for at least 12 months (for participants >=2 years of age) prior to screening, has experienced at least 1 VWF-treated bleeding event during (excluding menorrhagia/heavy menstrual bleeding [HMB], as applicable) in the last 12 months, and prophylactic treatment is recommended by the investigator (Prior OD participants); or
    2. The participant has been receiving prophylactic treatment with pdVWF products for at least 12 months prior to screening (for participants >=2 years of age) and switching to prophylaxis with vonicog alfa (rVWF) is recommended by the investigator (Switch participants).
    3. For participants \<2 years of age, the required duration for prior OD therapy with VWF products or for prior prophylactic treatment with pdVWF products is at least 6 months. Prior OD participants \<2 years of age should have experienced at least 1 VWF-treated bleeding event during the last 6 months based on medical records and be recommended to receive prophylactic treatment by the investigator.
  4. For participants >=2 years of age, the participant has available records that reliably evaluate type, frequency, severity, and treatment of BEs for at least 12 months preceding enrollment. For participants \<2 years of age, the participant has available records that reliably evaluate type, frequency, severity and treatment of BEs for at least 6 months preceding enrollment.
  5. If >=12 years old at the time of screening, the participant has a (BMI) >=15 but \<40 kilogram per square meter (kg/m\^2). If >=2 to \<12 years old at the time of screening, the participant has a BMI of >=5th and \<95th percentile (per Centers for Disease Control and Prevention [CDC] clinical charts). For younger participants who are \<2 years old, the "weight-for-age" clinical charts (5th to 95th percentile) provided by the CDC should be utilized to ensure the participant has a body weight of >=5th and \<95th percentile based on gender (for clinical charts provided by CDC, refer to: https://www.cdc.gov/growthcharts/clinical_charts.htm).
  6. Female participants of (that is, had onset of menses/reached puberty) must have a negative blood/urine pregnancy test result at screening and agree to employ highly effective measures for the duration of their participation in the study.
  7. The participant has voluntarily provided assent (if appropriate) and the legally authorized representative(s) has provided .
  8. The participant and/or legally authorized representative is willing and able to comply with the requirements of the protocol, which should also be confirmed based on a prescreening evaluation held between the investigator and the sponsor to ensure no eminent risk is present that could challenge the participant's compliance with the study requirements.

Exclusion Criteria:

  1. The participant has been diagnosed with pseudo VWD or another hereditary or acquired coagulation disorder other than VWD (example, qualitative and quantitative disorders or elevated /international normalized ratio 1.4).
  2. The participant has a history or presence of a VWF inhibitor at screening.
  3. The participant has a history or presence of an factor VIII (FVIII) inhibitor with a titer >=0.6 Bethesda units per milliliter (/mL).
  4. The participant has a known to any of the components of the study drugs, such as mouse or hamster proteins.
  5. The participant has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies, or animal allergies.
  6. The participant has a medical history of a thromboembolic event.
  7. The participant is (HIV)-positive with an absolute helper T cell (CD4) count \<200 per cubic millimeter or microliter (/mm\^3).
  8. The participant has been diagnosed with significant liver disease per the investigator's medical assessment of the participant's current condition or medical history or as evidenced by, but not limited to, any of the following: serum (ALT) greater than 5 times the (ULN), hypoalbuminemia, portal vein hypertension (example, presence of otherwise unexplained splenomegaly, history of esophageal varices), or liver cirrhosis classified as class B or C.
  9. The participant has been diagnosed with renal disease, with a serum creatinine level >=2.5 milligram per deciliter (mg/dL).
  10. The participant has a platelet count \<100,000/mL at screening (because participants with type 2B VWD are considered eligible for this study, for participants with type 2B VWD, platelet count[s] at screening will be evaluated in consultation with the sponsor, taking into consideration historical trends in platelet counts and the investigator's medical assessment of the participants condition).
  11. The participant has been treated with an immunomodulatory drug, excluding topical treatment (example, ointments, nasal sprays), within 30 days prior to signing the informed consent (or assent, if appropriate).
  12. The participant is pregnant or lactating at the time of enrollment.
  13. The participant has cervical or uterine conditions causing menorrhagia or metrorrhagia (including infection, dysplasia).
  14. The participant has participated in another clinical study involving another IP or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  15. The participant has not received OD or prophylactic treatment with a VWF product prior to this study.
  16. The participant has a progressive fatal disease and/or of less than 15 months.
  17. The participant is unable to complete screening procedures and/or comply with the requirements of the protocol in the opinion of the investigator, based on the joint prescreening evaluation held between the investigator and the sponsor.
  18. The participant has a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude.
  19. The participant is member of the study team or in a dependent relationship with one of the study team members, which includes close relatives (that is, children, partner/spouse, siblings, and parents) as well as employees.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Participants With Age >=12 to <18 years

    Participants with age greater than or equal to (\>=) 12 to less than (\<) 18 years who have received on-demand (OD) therapy or prophylactic treatment with a pdVWF product will receive vonicog alfa (rVWF) with an initial dose selected within the range of 40 to 60 international units per kilogram (IU/kg) vonicog alfa (rVWF), intravenous infusions, twice-weekly for 12 months. Participants may receive vonicog alfa (rVWF) with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).

    Biological: Vonicog Alfa · Biological: ADVATE

  • Experimental
    Cohort 2: Participants With Age >=6 to <12 years

    Participants with age \>=6 to \<12 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive vonicog alfa (rVWF) with an initial dose selected within the range of 40 to 60 IU/kg vonicog alfa (rVWF), intravenous infusions, twice-weekly for 12 months. Participants may receive vonicog alfa (rVWF) with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).

    Biological: Vonicog Alfa · Biological: ADVATE

  • Experimental
    Cohort 3: Participants With Age <6 years

    Participants with age \<6 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive vonicog alfa (rVWF) with an initial dose selected within the range of 40 to 60 IU/kg vonicog alfa (rVWF), intravenous infusions, twice-weekly for 12 months. Participants may receive vonicog alfa (rVWF) with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).

    Biological: Vonicog Alfa · Biological: ADVATE

Interventions

  • BiologicalVonicog Alfa

    Vonicog Alfa administered by intravenous injection.

    Also known as: TAK-577, Recombinant von Willebrand Factor (rVWF), Vonvendi-Veyvondi

  • BiologicalADVATE

    ADVATE administered by intravenous injection.

    Also known as: Recombinant Factor VIII (rFVIII), Octocog Alfa

06

What researchers measure

Primary outcomes

  1. Annualized Bleeding Rate (ABR) for Spontaneous or Traumatic Bleeding Episodes as Assessed by Investigator During Prophylactic Treatment With Vonicog Alfa (rVWF)

    ABR during the study compared to historical ABR for each participant for both spontaneous and traumatic bleeding episodes as classified by the investigator during prophylactic treatment with vonicog alfa (rVWF) will be reported.

    Time frame: 12 months

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of participants with TEAEs and SAEs will be reported.

    Time frame: 12 months

  2. Number of Participants With TEAEs by Severity

    Number of participants with severity of TEAE will be reported.

    Time frame: 12 months

  3. Number of Participants With TEAEs and SAEs by Causality

    Number of participants with causality related TEAEs and SAEs will be reported.

    Time frame: 12 months

  4. Number of Participants With Thromboembolic Events, Hypersensitivity Reactions and Infusion-Related Reactions (IRR)

    Number of participants with thromboembolic events, hypersensitivity reactions and IRR will be reported.

    Time frame: 12 months

  5. Number of Participants Who Develop Neutralizing Antibodies to VWF and Factor VIII (FVIII)

    Number of participants who develop neutralizing antibodies to VWF and FVIII will be reported.

    Time frame: 12 months

  6. Number of Participants Who Develop Binding Antibodies to VWF and FVIII

    Number of participants who develop total binding antibodies to VWF and FVIII will be reported.

    Time frame: 12 months

  7. Number of Participants With Clinically Significant Change From Baseline Values in Vital Sign Parameters

    Number of participants with clinically significant change from baseline values in vital sign parameters per investigator assessment will be reported.

    Time frame: 12 months

  8. Number of Participants With Clinically Significant Change From Baseline Values in Laboratory Parameters

    Number of participants with clinically significant change from baseline values in laboratory parameters per investigator assessment will be reported.

    Time frame: 12 months

  9. Number of Participants With Categorized ABR

    ABR categorized as 0, 0-2, 2-5, or \>5 bleeding episodes during vonicog alfa (rVWF) prophylaxis. Number of participants with categorized ABR will be reported.

    Time frame: 12 months

  10. Number of Participants Previously Receiving On-demand Treatment who will Achieve ABR Percent Reduction Success

    ABR percent reduction success is defined as at least 25% reduction of ABR during vonicog alfa (rVWF) prophylaxis relative to the participant's own historical ABR during OD treatment prior to enrollment in this study. Number of participants previously receiving on-demand treatment who will achieve ABR percent reduction success will be reported.

    Time frame: 12 months

  11. Number of pdVWF Switch Participants With Spontaneous ABR Preservation Success

    ABR preservation success is defined as achieving an ABR for spontaneous bleeding episodes during vonicog alfa (rVWF) prophylaxis that is no greater than the participant's own historical ABR during prophylactic treatment with pdVWF prior to enrollment in this study. Number of pdVWF switch participants with spontaneous ABR preservation success will be reported.

    Time frame: 12 months

  12. Number of Spontaneous ABR Historically and While on Prophylactic Treatment With Vonicog Alfa (rVWF) by Location of Bleeding

    Number of spontaneous ABR historically and while on prophylactic treatment with vonicog alfa (rVWF) by location of bleeding will be reported.

    Time frame: 12 months

  13. ABR for Bleeding Episodes by Bleeding Cause Historically and While on Prophylactic Treatment With Vonicog Alfa (rVWF)

    ABR for bleeding episodes by bleeding cause historically and while on prophylactic treatment with vonicog alfa (rVWF) will be reported.

    Time frame: 12 months

  14. Total Number of Infusions Administered Per Week During Prophylactic Treatment With Vonicog Alfa (rVWF)

    Total number of infusions administered per week during prophylactic treatment with vonicog alfa (rVWF) will be reported.

    Time frame: 12 months

  15. Average Number of Infusions Per Week During Prophylactic Treatment With Vonicog Alfa (rVWF)

    Average number of infusions per week during prophylactic treatment with vonicog alfa (rVWF) will be reported.

    Time frame: 12 months

  16. Total Weight Adjusted Consumption of Vonicog Alfa (rVWF) Per Month During Prophylactic Treatment

    Total weight adjusted consumption of vonicog alfa (rVWF) per month during prophylactic treatment will be reported.

    Time frame: 12 months

  17. Overall Hemostatic Efficacy Rating of Breakthrough Bleed Treatment at Resolution of the Bleeding Episode

    Overall hemostatic efficacy rating of breakthrough bleed treatment at resolution of the bleeding episode will be reported.

    Time frame: 12 months

  18. Number of Infusions of rVWF and ADVATE (rFVIII, octocog alfa) per Bleeding Episode

    Number of infusions of vonicog alfa (rVWF) and ADVATE per bleeding episode will be reported.

    Time frame: 12 months

  19. Weight-adjusted Consumption of Vonicog Alfa (rVWF) and ADVATE per Bleeding Episode

    Weight-adjusted consumption of vonicog alfa (rVWF) and ADVATE per bleeding episode will be reported.

    Time frame: 12 months

  20. Plasma Level of Vonicog Alfa (rVWF) based on Von Willebrand Factor: Ristocetin Cofactor (VWF:Rco)

    Plasma level of vonicog alfa (rVWF) based on VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  21. Plasma Level of Vonicog Alfa (rVWF) based on Von Willebrand Factor Antigen (VWF:Ag)

    Plasma level of vonicog alfa (rVWF) based on VWF:Ag will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  22. Plasma Level of Vonicog alfa (rVWF) based on Von Willebrand Factor Collagen Binding (VWF:CB)

    Plasma level of vonicog alfa (rVWF) based on VWF:CB will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  23. Plasma Level of Vonicog alfa (rVWF) based on Von Willebrand Factor Glycoprotein 1b Binding (VWF:GP1bM)

    Plasma level of vonicog alfa (rVWF) based on VWF:GP1bM will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  24. Plasma Level of Factor VIII Clotting (FVIII:C)

    Plasma level of FVIII:C will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  25. Incremental Recovery Based on VWF:Rco

    Incremental recovery based on VWF:Rco will be reported.

    Time frame: 12 months

  26. Incremental Recovery Based on VWF:Ag

    Incremental recovery based on VWF:Ag will be reported.

    Time frame: 12 months

  27. Incremental Recovery Based on VWF:CB

    Incremental recovery based on VWF:CB will be reported.

    Time frame: 12 months

  28. Incremental Recovery Based on VWF:GP1bM

    Incremental recovery based on VWF:GP1bM will be reported.

    Time frame: 12 months

  29. Ratio of Area Under the Plasma Level Versus Time Curve From Time 0 to End of the Partial Dosing Interval (AUC0- Tau;ss) and Area Under the Level Versus Time Curve From 0 to 96 Hours (AUC0-96; ss) for VWF:Rco

    Ratio of AUC0- Tau;ss/AUC0-96; ss for VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  30. Terminal Half-life (T1/2) for VWF:Rco

    TT1/2 based on VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  31. Maximum Plasma Level During the Partial Dosing Interval at Steady State (Cmax;ss) for VWF:Rco

    Cmax;ss for VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  32. Minimum Time to Reach the Maximum Plasma Level at Steady State (Tmax;ss) for VWF:Rco

    Tmax;ss for VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  33. Volume of Distribution at Steady State (Vss) for VWF:Rco

    Vss for VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  34. Clearance (CL) for VWF:Rco

    CL for VWF:Rco will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  35. Maximum Plasma Level During the Partial Dosing Interval at Steady State (Cmax;ss) for FVIII:C

    Cmax;ss for FVIII:C will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  36. Minimum Time to Reach the Maximum Plasma Level at Steady State (Tmax;ss) for FVIII:C

    Tmax;ss for FVIII:C will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  37. Ratio of Area Under the Plasma Level Versus Time Curve From Time 0 to End of the Partial Dosing Interval (AUC0- Tau;ss) and Area Under the Level Versus Time Curve From 0 to 96 Hours (AUC0-96; ss) for FVIII:C

    Ratio of AUC0- Tau;ss and AUC0-96; ss for FVIII:C will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

  38. Area Under the Level Versus Time Curve From 0 to 96 Hours (AUC0-96; ss) for FVIII:C

    AUC0-96; ss for FVIII:C will be reported.

    Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion

07

Study locations

19 of 23 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35223, United States
    Recruiting
    • Site Contact · Contactcbstolz@uabmc.edu · 205-638-9285
    • Christina Bemrich-Stolz · Principal investigator
  • Arnold Palmer Childrens Hosptial
    Orlando, Florida 32806, United States
    Not yet recruiting
  • Bleeding and Clotting Disorders Institute
    Peoria, Illinois 61614, United States
    Recruiting
    • Site Contact · Contactjroberts@ilbcdi.org · 309-692-5337
    • Jonathan Roberts · Principal investigator
  • Riley Hospital for Children Indiana University Health
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Site Contact · Contactkmfitzpa@iu.edu · 317-944-2143
    • Kerry Hege · Principal investigator
  • University of Iowa Hospitals & Clinics PARENT
    Iowa City, Iowa 52242, United States
    Recruiting
  • Childrens Hospital of Michigan
    Detroit, Michigan 48201, United States
    Recruiting
    • Site Contact · ContactRajpu1ma@cmich.edu · 313-745-5515
    • Madhvi Rajpurkar · Principal investigator
  • Michigan State University Center for Bleeding Disorders & Clotting Disorders
    East Lansing, Michigan 48824, United States
    Not yet recruiting
    • Site Contact · Contactsoodaari@msu.edu · 517-353-9385
    • David Cervi · Principal investigator
  • Children's Health Care d/b/a Children's Minnesota
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • Cure 4 the Kids
    Las Vegas, Nevada 89135, United States
    Recruiting
  • Rutgers - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • New York - Presbyterian/Weill Cornell Medical Center
    New York, New York 10021, United States
    Recruiting
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
    Recruiting
    • Site Contact · Contactbergmans@musc.edu · 843-792-2957
    • Shayla Bergmann · Principal investigator
  • Hemostase Clinique - Institut Cœur-Poumons (4eme étage aile est) Bureau 419
    Lille, 59037, France
    Recruiting
  • Hopital Edouard Herriot - CHU Lyon
    Lyon, 69677, France
    Recruiting
  • Children's Health Ireland
    Dublin, D12N512, Ireland
    Recruiting
  • Azienda Ospedaliera Pediatrica Santobono Pausillipon
    Naples, 80123, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
    Turin (Torino), 10126, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Japanese Red Cross Narita Hospital
    Narita, Chiba 286-8523, Japan
    Recruiting
  • Nara Medical University Hospital
    Kashihara, Nara 634-8522, Japan
    Recruiting
  • NHO Beppu Medical Center
    Beppu, Oita Prefecture 874-0011, Japan
    Recruiting
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
    Recruiting
  • Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust
    London, WC1N 3HR, United Kingdom
    Recruiting
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, OX3 9DU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Apr 2030, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 17, 2022
StartActual
Nov 6, 2024
Primary completionEst.
Apr 11, 2030
CompletionEst.
Apr 11, 2030
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05582993
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Nov 6, 2024
Primary completion
Apr 11, 2030 (estimated)
Completion
Apr 11, 2030 (estimated)
Last update
Sep 9, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonicog alfa

Start the discussion